Incyte
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.About INCY
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.
INCY Key Statistics
Stock Snapshot
With a market cap of 23.75B, Incyte(INCY) trades at $117.23. The stock has a price-to-earnings ratio of 15.47.
During the trading session on 2026-10-02, Incyte(INCY) shares reached a daily high of $117.23 and a low of $117.23. At a current price of $117.23, the stock is 0.0% higher than the low and still 0.0% under the high.
Trading activity shows a volume of 628, compared to an average daily volume of 1.79M.
The stock's 52-week range extends from a low of $82.82 to a high of $132.60.
The stock's 52-week range extends from a low of $82.82 to a high of $132.60.
INCY News
...
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY Quick QuoteINCY - Free Report) and Techne (TECH Qui...
Mirum Pharmaceuticals and Incyte reported that the FDA approved Atebrioz (zilurgisertib), an oral ALK2 inhibitor for Fibrodysplasia Ossificans Progressiva in pa...
Analyst ratings
52%
of 31 ratingsMore INCY News
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Incyte, with a price target of $152.00. Mitchell Kapoor has given hi...
Incyte (INCY) moved back into focus after the U.S. FDA cleared Atebrioz tablets for fibrodysplasia ossificans progressiva and granted the company a Rare Pediatr...
JPMorgan analyst Jessica Fye raised the firm’s price target on Incyte (INCY) to $123 from $120 and keeps a Neutral rating on the shares. Published first on The...
The U.S. Food and Drug Administration (FDA) on Friday approved Atebrioz (zilurgisertib) tablets, delivering a new once-daily oral treatment to patients sufferin...
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Incyte today and set a price target of $152.00. Mitchell Kapoor has given his Buy rating due...
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced that the U.S. FDA has approved Atebrioz tablets to reduce the volume of total new heterotopic ossificat...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.